Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

389

HTML

2854

Tables (1-5)

170

Sum=3413

Nov 21, 2005 (publication date) through Nov 2, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Nov 21, 2005; 11(43): 6823-6827
Published online Nov 21, 2005. doi: 10.3748/wjg.v11.i43.6823

Table 3 Results of treatment

	Treatment regimen
	Cefotaxime (%)	Amikacin (%)	P
Number of patients	19	18
Cure²	15 (78.9)	11 (61.1)	NS
Normalized PMN count²	18 (94.7)	15 (83.3)	NS
Serum creatinine(mg/dL)¹	1.3 ± 0.8	1.5 ± 1.1	NS
Afebril in 72 h²	18 (94.7)	15 (83.3)	NS
Pain-free in 72 h²	19 (100)	17 (94.4)	NS
Recurrence²	3(15.8)	0	NS
Superinfection²	0	0	NS
Infection-related mortality²	0	3 (16.7)	0.105
Hospitalization mortality²	4 (21.1)	5 (27.8)	NS
Days of hospitalization¹	12 ± 8	13 ± 9	NS

¹Data are presented as mean ± SD.

²Data are presented as number and percentage of total. NS: not significant

Citation: Chen TA, Lo GH, Lai KH, Lin WJ. Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics. World J Gastroenterol 2005; 11(43): 6823-6827
URL: https://www.wjgnet.com/1007-9327/full/v11/i43/6823.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i43.6823